ALLERGAN ANNOUNCES THE LATISSE™ WISHES CAMPAIGN, COMMITTING $1 MILLION TO THE MAKE-A-WISH FOUNDATION®
Register on LATISSE™ Web Site to Help Reach Goal
(IRVINE, Calif., March 27, 2009) /PRNewswire/ — Allergan, Inc. (NYSE: AGN) hosted a star-studded event last night in Hollywood to launch LATISSE™ Wishes, a charitable public awareness campaign designed to help make wishes come true. Actress Brooke Shields and beauty expert to the stars Anastasia Soare will lead the campaign to generate $1 million to support the Make-A-Wish Foundation, a non-profit organization dedicated to granting the wishes of children with life-threatening medical conditions.
The LATISSE™ Wishes campaign was borne out of the tradition of blowing on an eyelash to make a wish come true and leverages the excitement surrounding the availability of Allergan's LATISSE™ (bimatoprost ophthalmic solution) 0.03%, the first and only science-based prescription treatment approved by the U.S. Food and Drug Administration for hypotrichosis of the eyelashes (inadequate or not enough lashes) that is used to grow eyelashes, making them longer, fuller and darker.
"In the short time LATISSE™ has been available, the product has already made many women's wish lists," said David E. I. Pyott, Chairman of the Board and Chief Executive Officer of Allergan. "While LATISSE™ may fulfill the wish for more prominent eyelashes, we also wanted to shine the spotlight on the Make-A-Wish Foundation and provide support for the important work it does in granting children's wishes."
The LATISSE™ Wishes campaign launched with an initial donation of $500,000 from Allergan to the Make-A-Wish Foundation. Consumers are encouraged to help double this amount to $1 million by registering their support at www.LATISSE.com to help grant the wishes of children in their local communities. Between now and December 31, 2009, Allergan will donate $5 for each new visitor who registers online, up to an additional $500,000.
"Every 40 minutes the Make-A-Wish Foundation grants a wish to a child with a life-threatening medical condition. Forty seconds is all it takes to visit www.LATISSE.com to register your support and help make wishes come true," said David Williams, president and chief executive officer of the Make-A-Wish Foundation. "We urge everyone to log on to the LATISSE™ Web site and register their support to help grant the wishes of children in their communities."
"I am delighted to be a part of LATISSE™ Wishes, to not only help educate women on an eyelash growth product that is the first to be scientifically proven, but also to support a worthy organization such as the Make-A-Wish Foundation," said Shields. "I remember being a child and blowing on an eyelash hoping my wish would come true, and as a mother I've passed this tradition onto my children. Through LATISSE™ Wishes and in partnership with Make-A-Wish Foundation, we can keep the tradition alive and fulfill the hopes of so many more children around the country."
In addition to Shields and Soare, other stars including Debra Messing, Angie Harmon, Marisa Tomei, Mandy Moore, Debi Mazar, Jewel, Jennifer Coolidge and Perrey Reeves attended last night's red-carpet kick-off event for the LATISSE™ Wishes campaign. Over the next several months, campaign ambassadors Shields and Soare, who both use LATISSE™ solution, will travel to cities across the country hosting informational events aimed to further support the campaign and its goal of providing $1 million to the Make-A-Wish Foundation. Local events will be held in New York, Miami, Dallas, Minneapolis and San Francisco.
"In my business I constantly work to help make women's beauty wishes come true and now we can help children's wishes come true through the LATISSE™ Wishes campaign," said Soare. "I am excited to bring this worthy campaign to cities across the country."
For more information about the LATISSE™ Wishes charitable awareness campaign, please visit www.LATISSE.com.
LATISSE™ (bimatoprost ophthalmic solution) 0.03% is a prescription treatment for hypotrichosis used to grow eyelashes, making them longer, thicker and darker. Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes. The once-daily prescription treatment is applied to the base of the upper eyelashes with a sterile single-use-per-eye disposable applicator. While individual results may vary, LATISSE™ users can expect to experience results in as little as eight weeks, with significant results in 16 weeks. To maintain effect, continued treatment with LATISSE™ solution is required, and if use of LATISSE™ is discontinued, eyelashes will gradually return to where they were prior to treatment over a period of several weeks to months (average eyelash hair cycle).
Important LATISSE™ Information
LATISSE™ (bimatoprost ophthalmic solution) 0.03% is a prescription treatment for hypotrichosis used to grow eyelashes, making them longer, thicker and darker. Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes.
LATISSE™ Important Safety Information
Do not use LATISSE™ solution if you are allergic to one of its ingredients.
LATISSE™ solution is intended for use on the skin of the upper eyelid margins at the base of the eyelashes. If you have a history of abnormal intraocular pressure (IOP), you should only use LATISSE™ under the close supervision of your physician.
LATISSE™ use may cause darkening of the eyelid skin which may be reversible. LATISSE™ use may also cause increased brown pigmentation of the colored part of the eye which is likely to be permanent.
If you are using other prescription products for lowering eye pressure or have a history of eye pressure problems, use LATISSE™ under close physician supervision.
If you develop or experience any eye problems, eyelid reactions, or have eye surgery, consult your physician immediately about the continued use of LATISSE™.
The most common side effects after using LATISSE™ solution are an itching sensation in the eyes and/or eye redness. This was reported in approximately 4% of patients. LATISSE™ solution may cause other less common side effects which typically occur on the skin close to where LATISSE™ is applied, or in the eyes. These include skin darkening, eye irritation, dryness of the eyes, and redness of the eyelids.
About Make-A-Wish Foundation
The Make-A-Wish Foundation® grants the wishes of children with life-threatening medical conditions to enrich the human experience with hope, strength and joy. Founded in 1980 when a group of caring volunteers helped a young boy fulfill his dream of becoming a police officer, the Foundation is now the largest wish-granting charity in the world, with 66 chapters in the United States and its territories. With the help of generous donors and nearly 25,000 volunteers, the Make-A-Wish Foundation grants a wish every 40 minutes and has granted more than 174,000 wishes in the United States since its inception. For more information about the Make-A-Wish Foundation, visit wish.org and discover how you can share the power of a wish®.
About Allergan, Inc.
Founded in 1950, Allergan, Inc., with headquarters in Irvine, California, is a multi-specialty health care company that discovers, develops and commercializes innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully. The Company employs more than 8,500 people worldwide and operates state-of-the-art R&D facilities and world-class manufacturing plants. In addition to its discovery-to-development research organization, Allergan has global marketing and sales capabilities with a presence in more than 100 countries.
Allergan Medical, a division of Allergan, Inc., offers the most comprehensive, science-based, aesthetic product offerings under its Total Facial Rejuvenation™ portfolio, including BOTOX® Cosmetic; hyaluronic acid and collagen-based dermal fillers; and physician-dispensed skin care products. Allergan Medical also offers the industry's widest range of silicone gel-filled and saline-filled breast implant options for reconstructive and aesthetic breast surgery, and leading minimally invasive devices for obesity intervention treatment.
This press release contains "forward-looking statements", including statements regarding research and development outcomes, efficacy, adverse events, market and product potential and other statements regarding LATISSE™.
These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's expectations and projections. Risks and uncertainties include, among other things, general industry and market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to product marketing, such as the unpredictability of market acceptance for new products and/or the acceptance of new indications for such products; inconsistency of treatment results among patients and the potential for product failures; unknown risks associated with the investigational devices that are the subject of clinical trials; potential difficulties in manufacturing new products; general economic conditions; and governmental laws and regulations affecting domestic and foreign operations. Allergan expressly disclaims any intent or obligation to update these forward-looking statements except as required to do so by law.
Additional information concerning these and other risk factors can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Allergan's 2008 Form 10-K. Copies of Allergan's press releases and additional information about Allergan is available on the World Wide Web at www.allergan.com or you can contact the Allergan Investor Relations Department by calling (714) 246-4636.
Share the power of a wish® is owned by the Make-A-Wish Foundation®.
© 2008 Allergan, Inc. Irvine, CA 92612. ™ and ® marks owned by Allergan, Inc.